45 results on '"Odenstedt, Jacob"'
Search Results
2. Characteristics and Outcomes of Patients Receiving a Second Rescue Valve During Transcatheter Aortic Valve Implantation
- Author
-
Bjursten, Henrik, Koul, Sasha, Pétursson, Pétur, Odenstedt, Jacob, Hagstrom, Henrik, Backes, Jenny, Nielsen, Niels Erik, Rück, Andreas, Johansson, Jan, James, Stefan, Settergren, Magnus, Götberg, Matthias, Yndigen, Troels, Bjursten, Henrik, Koul, Sasha, Pétursson, Pétur, Odenstedt, Jacob, Hagstrom, Henrik, Backes, Jenny, Nielsen, Niels Erik, Rück, Andreas, Johansson, Jan, James, Stefan, Settergren, Magnus, Götberg, Matthias, and Yndigen, Troels
- Abstract
Background Transcatheter aortic valve implantation (TAVI) has become a safe procedure. However, complications occur, including uncommon complications such as valve malposition, which requires the implantation of an additional rescue valve (rescue-AV). The aim was to study the occurrence and outcomes of rescue-AV in a nationwide registry. Methods The Swedish national TAVI registry was used as the primary data source, where all 6706 TAVI procedures from 2016 to 2021 were retrieved. Nontransfemoral access and planned valve-in-valve were excluded. In total, 79 patients were identified as having had a rescue-AV, and additional detailed data were collected for these patients. This dataset was analyzed for any characteristics that could predispose patients to a rescue-AV. The outcome of patients receiving rescue-AV also was studied. Results Of the 5948 patients in the study, 1.3% had a rescue-AV. There were few differences between patients receiving 1 valve and rescue-AV patients. For patients receiving a rescue-AV, the 30-day mortality was 15.2% compared to 1.6% in the control group. A poor outcome after rescue-AV was often associated with a second complication; for example, stroke, need for emergency surgery, or heart failure. Among the patients with rescue-AV who survived at least 30 days, landmark analyses showed similar survival rates compared to the control group. Conclusions Among TAVI patients in a nationwide register, rescue-AV occurred in 1.3% of patients. The 30-day mortality in patients receiving rescue-AV was high, but long-term outcome among 30-day survivors was similar to the control group.
- Published
- 2024
- Full Text
- View/download PDF
3. Unintended Deformation of Stents During Bifurcation PCI: An OCTOBER Trial Substudy
- Author
-
Andreasen, Lene Nyhu, Neghabat, Omeed, Laanmets, Peep, Kumsars, Induli, Bennett, Johan, Olsen, Niels T, Odenstedt, Jacob, Burzotta, Francesco, Johnson, Thomas W, O'Kane, Peter, Hartikainen, Juha E K, Spratt, James C, Christiansen, Evald H, Holm, Niels R, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Andreasen, Lene Nyhu, Neghabat, Omeed, Laanmets, Peep, Kumsars, Induli, Bennett, Johan, Olsen, Niels T, Odenstedt, Jacob, Burzotta, Francesco, Johnson, Thomas W, O'Kane, Peter, Hartikainen, Juha E K, Spratt, James C, Christiansen, Evald H, Holm, Niels R, and Burzotta, Francesco (ORCID:0000-0002-6569-9401)
- Abstract
Background: Unintended deformation of implanted coronary stents can lead to loss of coronary access, stent thrombosis and coronary events during follow-up. The incidence, mechanisms and clinical outcomes of unintended stent deformations (USD) during complex bifurcation stenting are not well characterized. Objectives: In a prespecified analysis of the OCTOBER (European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction) trial, we aimed to: 1) determine the incidence and characterize mechanisms of USD identified by optical coherence tomography (OCT); and 2) evaluate physician's detection and correction of accidental abluminal rewiring and USD. Methods: OCT scans were analyzed for accidental abluminal rewiring and USD. When USD was identified, the plausible mechanism was determined by analysis of all procedural OCT scans and the corresponding angiograms. Results: USD was identified by the core lab in 9.3% (55/589) of OCT-guided cases. Accidental abluminal rewiring was the cause in 44% (24/55), and guide catheter collision was the cause in 40% (22/55) of cases. USD was found in 18.5% of all cases with left main bifurcation percutaneous coronary intervention. The total incidence of abluminal rewiring was 33 in 32 OCT-guided cases (5.4%) and was corrected by physicians in 18 of 33 appearances (54.5%). The 2-year major adverse cardiac event rate for patients with untreated USD (n = 30) was 23.3%, whereas patients with confirmed or possibly corrected USD (n = 25) had no events during follow-up. Conclusions: USD was associated with adverse procedural complications and cardiac events during follow-up when not identified and corrected. The predominant mechanisms were undetected abluminal rewiring and guide catheter collision. Left main bifurcation percutaneous coronary intervention was a particular risk with USD detected in 18.5% of cases.
- Published
- 2024
4. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions
- Author
-
Holm, Niels R, Andreasen, Lene N, Neghabat, Omeed, Laanmets, Peep, Kumsars, Induli, Bennett, Johan, Olsen, Niels T, Odenstedt, Jacob, Hoffmann, Pavel, Dens, Jo, Chowdhary, Saqib, O'Kane, Peter, Bülow Rasmussen, Søren-Haldur, Heigert, Matthia, Havndrup, Ole, Van Kuijk, Jan P, Biscaglia, Simone, Mogensen, Lone J H, Henareh, Loghman, Burzotta, Francesco, H Eek, Christian, Mylotte, Darren, Llinas, Miquel S, Koltowski, Lukasz, Knaapen, Paul, Calic, Slobodan, Witt, Nil, Santos-Pardo, Irene, Watkins, Stuart, Lønborg, Jacob, Kristensen, Andreas T, Jensen, Lisette O, Calais, Fredrik, Cockburn, Jame, Mcneice, Andrew, Kajander, Olli A, Heestermans, Ton, Kische, Stephan, Eftekhari, Ashkan, Spratt, James C, Christiansen, Evald H, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Holm, Niels R, Andreasen, Lene N, Neghabat, Omeed, Laanmets, Peep, Kumsars, Induli, Bennett, Johan, Olsen, Niels T, Odenstedt, Jacob, Hoffmann, Pavel, Dens, Jo, Chowdhary, Saqib, O'Kane, Peter, Bülow Rasmussen, Søren-Haldur, Heigert, Matthia, Havndrup, Ole, Van Kuijk, Jan P, Biscaglia, Simone, Mogensen, Lone J H, Henareh, Loghman, Burzotta, Francesco, H Eek, Christian, Mylotte, Darren, Llinas, Miquel S, Koltowski, Lukasz, Knaapen, Paul, Calic, Slobodan, Witt, Nil, Santos-Pardo, Irene, Watkins, Stuart, Lønborg, Jacob, Kristensen, Andreas T, Jensen, Lisette O, Calais, Fredrik, Cockburn, Jame, Mcneice, Andrew, Kajander, Olli A, Heestermans, Ton, Kische, Stephan, Eftekhari, Ashkan, Spratt, James C, Christiansen, Evald H, and Burzotta, Francesco (ORCID:0000-0002-6569-9401)
- Abstract
Background: Imaging-guided percutaneous coronary intervention (PCI) is associated with better clinical outcomes than angiography-guided PCI. Whether routine optical coherence tomography (OCT) guidance in PCI of lesions involving coronary-artery branch points (bifurcations) improves clinical outcomes as compared with angiographic guidance is uncertain. Methods: We conducted a multicenter, randomized, open-label trial at 38 centers in Europe. Patients with a clinical indication for PCI and a complex bifurcation lesion identified by means of coronary angiography were randomly assigned in a 1:1 ratio to OCT-guided PCI or angiography-guided PCI. The primary end point was a composite of major adverse cardiac events (MACE), defined as death from a cardiac cause, target-lesion myocardial infarction, or ischemia-driven target-lesion revascularization at a median follow-up of 2 years. Results: We assigned 1201 patients to OCT-guided PCI (600 patients) or angiography-guided PCI (601 patients). A total of 111 patients (18.5%) in the OCT-guided PCI group and 116 (19.3%) in the angiography-guided PCI group had a bifurcation lesion involving the left main coronary artery. At 2 years, a primary end-point event had occurred in 59 patients (10.1%) in the OCT-guided PCI group and in 83 patients (14.1%) in the angiography-guided PCI group (hazard ratio, 0.70; 95% confidence interval, 0.50 to 0.98; P = 0.035). Procedure-related complications occurred in 41 patients (6.8%) in the OCT-guided PCI group and 34 patients (5.7%) in the angiography-guided PCI group. Conclusions: Among patients with complex coronary-artery bifurcation lesions, OCT-guided PCI was associated with a lower incidence of MACE at 2 years than angiography-guided PCI. (Funded by Abbott Vascular and others; OCTOBER ClinicalTrials.gov number, NCT03171311.).
- Published
- 2023
5. Characteristics and outcomes of patients receiving a second rescue valve during transcatheter aortic valve implantation
- Author
-
Bjursten, Henrik, Koul, Sasha, Pétursson, Pétur, Odenstedt, Jacob, Hagström, Henrik, Backes, Jenny, Nielsen, Niels Erik, Rück, Andreas, Johansson, Jan, James, Stefan, Settergren, Magnus, Götberg, Matthias, Yndigen, Troels, Bjursten, Henrik, Koul, Sasha, Pétursson, Pétur, Odenstedt, Jacob, Hagström, Henrik, Backes, Jenny, Nielsen, Niels Erik, Rück, Andreas, Johansson, Jan, James, Stefan, Settergren, Magnus, Götberg, Matthias, and Yndigen, Troels
- Abstract
Background: Transcatheter aortic valve implantation (TAVI) has become a safe procedure. However, complications occur, including uncommon complications such as valve malposition, which requires the implantation of an additional rescue valve (rescue-AV). The aim was to study the occurrence and outcomes of rescue-AV in a nationwide registry. Methods: The Swedish national TAVI registry was used as the primary data source, where all 6706 TAVI procedures from 2016 to 2021 were retrieved. Nontransfemoral access and planned valve-in-valve were excluded. In total, 79 patients were identified as having had a rescue-AV, and additional detailed data were collected for these patients. This dataset was analyzed for any characteristics that could predispose patients to a rescue-AV. The outcome of patients receiving rescue-AV also was studied. Results: Of the 5948 patients in the study, 1.3% had a rescue-AV. There were few differences between patients receiving 1 valve and rescue-AV patients. For patients receiving a rescue-AV, the 30-day mortality was 15.2% compared to 1.6% in the control group. A poor outcome after rescue-AV was often associated with a second complication; for example, stroke, need for emergency surgery, or heart failure. Among the patients with rescue-AV who survived at least 30 days, landmark analyses showed similar survival rates compared to the control group. Conclusions: Among TAVI patients in a nationwide register, rescue-AV occurred in 1.3% of patients. The 30-day mortality in patients receiving rescue-AV was high, but long-term outcome among 30-day survivors was similar to the control group.
- Published
- 2023
- Full Text
- View/download PDF
6. Characteristics and outcomes of patients receiving a second rescue valve during transcatheter aortic valve implantation
- Author
-
Bjursten, Henrik, Koul, Sasha, Pétursson, Pétur, Odenstedt, Jacob, Hagström, Henrik, Backes, Jenny, Nielsen, Niels Erik, Rück, Andreas, Johansson, Jan, James, Stefan, Settergren, Magnus, Götberg, Matthias, Yndigen, Troels, Bjursten, Henrik, Koul, Sasha, Pétursson, Pétur, Odenstedt, Jacob, Hagström, Henrik, Backes, Jenny, Nielsen, Niels Erik, Rück, Andreas, Johansson, Jan, James, Stefan, Settergren, Magnus, Götberg, Matthias, and Yndigen, Troels
- Abstract
Background: Transcatheter aortic valve implantation (TAVI) has become a safe procedure. However, complications occur, including uncommon complications such as valve malposition, which requires the implantation of an additional rescue valve (rescue-AV). The aim was to study the occurrence and outcomes of rescue-AV in a nationwide registry. Methods: The Swedish national TAVI registry was used as the primary data source, where all 6706 TAVI procedures from 2016 to 2021 were retrieved. Nontransfemoral access and planned valve-in-valve were excluded. In total, 79 patients were identified as having had a rescue-AV, and additional detailed data were collected for these patients. This dataset was analyzed for any characteristics that could predispose patients to a rescue-AV. The outcome of patients receiving rescue-AV also was studied. Results: Of the 5948 patients in the study, 1.3% had a rescue-AV. There were few differences between patients receiving 1 valve and rescue-AV patients. For patients receiving a rescue-AV, the 30-day mortality was 15.2% compared to 1.6% in the control group. A poor outcome after rescue-AV was often associated with a second complication; for example, stroke, need for emergency surgery, or heart failure. Among the patients with rescue-AV who survived at least 30 days, landmark analyses showed similar survival rates compared to the control group. Conclusions: Among TAVI patients in a nationwide register, rescue-AV occurred in 1.3% of patients. The 30-day mortality in patients receiving rescue-AV was high, but long-term outcome among 30-day survivors was similar to the control group.
- Published
- 2023
- Full Text
- View/download PDF
7. Impact of Computational Modeling on Transcatheter Left Atrial Appendage Closure Efficiency and Outcomes
- Author
-
De Backer, Ole, Iriart, Xavier, Kefer, Joelle, Nielsen-Kudsk, Jens Erik, Aminian, Adel, Rosseel, Liesbeth, Kofoed, Klaus Fuglsang, Odenstedt, Jacob, Berti, Sergio, Saw, Jacqueline, Søndergaard, Lars, Garot, Philippe, De Backer, Ole, Iriart, Xavier, Kefer, Joelle, Nielsen-Kudsk, Jens Erik, Aminian, Adel, Rosseel, Liesbeth, Kofoed, Klaus Fuglsang, Odenstedt, Jacob, Berti, Sergio, Saw, Jacqueline, Søndergaard, Lars, and Garot, Philippe
- Abstract
Background: When performing transcatheter left atrial appendage (LAA) closure, peridevice leaks and device-related thrombus (DRT) have been associated with worse clinical outcomes—hence, their risk should be mitigated. Objectives: The authors sought to assess whether use of preprocedural computational modeling impacts procedural efficiency and outcomes of transcatheter LAA closure. Methods: The PREDICT-LAA trial (NCT04180605) is a prospective, multicenter, randomized trial in which 200 patients were 1:1 randomized to standard planning vs cardiac computed tomography (CT) simulation–based planning of LAA closure with Amplatzer Amulet. The artificial intelligence–enabled CT-based anatomical analyses and computer simulations were provided by FEops (Belgium). Results: All patients had a preprocedural cardiac CT, 197 patients underwent LAA closure, and 181 of these patients had a postprocedural CT scan (standard, n = 91; CT + simulation, n = 90). The composite primary endpoint, defined as contrast leakage distal of the Amulet lobe and/or presence of DRT, was observed in 41.8% in the standard group vs 28.9% in the CT + simulation group (relative risk [RR]: 0.69; 95% CI: 0.46-1.04; P = 0.08). Complete LAA closure with no residual leak and no disc retraction into the LAA was observed in 44.0% vs 61.1%, respectively (RR: 1.44; 95% CI: 1.05-1.98; P = 0.03). In addition, use of computer simulations resulted in improved procedural efficiency with use of fewer Amulet devices (103 vs 118; P < 0.001) and fewer device repositionings (104 vs 195; P < 0.001) in the CT + simulation group. Conclusions: The PREDICT-LAA trial demonstrates the possible added value of artificial intelligence–enabled, CT-based computational modeling when planning for transcatheter LAA closure, leading to improved procedural efficiency and a trend toward better procedural outcomes.
- Published
- 2023
8. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions
- Author
-
Holm, Niels R, Andreasen, Lene N, Neghabat, Omeed, Laanmets, Peep, Kumsars, Induli, Bennett, Johan, Olsen, Niels T, Odenstedt, Jacob, Hoffmann, Pavel, Dens, Jo, Chowdhary, Saqib, O'Kane, Peter, Bülow Rasmussen, Søren-Haldur, Heigert, Matthia, Havndrup, Ole, Van Kuijk, Jan P, Biscaglia, Simone, Mogensen, Lone J H, Henareh, Loghman, Burzotta, Francesco, H Eek, Christian, Mylotte, Darren, Llinas, Miquel S, Koltowski, Lukasz, Knaapen, Paul, Calic, Slobodan, Witt, Nil, Santos-Pardo, Irene, Watkins, Stuart, Lønborg, Jacob, Kristensen, Andreas T, Jensen, Lisette O, Calais, Fredrik, Cockburn, Jame, Mcneice, Andrew, Kajander, Olli A, Heestermans, Ton, Kische, Stephan, Eftekhari, Ashkan, Spratt, James C, Christiansen, Evald H, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Holm, Niels R, Andreasen, Lene N, Neghabat, Omeed, Laanmets, Peep, Kumsars, Induli, Bennett, Johan, Olsen, Niels T, Odenstedt, Jacob, Hoffmann, Pavel, Dens, Jo, Chowdhary, Saqib, O'Kane, Peter, Bülow Rasmussen, Søren-Haldur, Heigert, Matthia, Havndrup, Ole, Van Kuijk, Jan P, Biscaglia, Simone, Mogensen, Lone J H, Henareh, Loghman, Burzotta, Francesco, H Eek, Christian, Mylotte, Darren, Llinas, Miquel S, Koltowski, Lukasz, Knaapen, Paul, Calic, Slobodan, Witt, Nil, Santos-Pardo, Irene, Watkins, Stuart, Lønborg, Jacob, Kristensen, Andreas T, Jensen, Lisette O, Calais, Fredrik, Cockburn, Jame, Mcneice, Andrew, Kajander, Olli A, Heestermans, Ton, Kische, Stephan, Eftekhari, Ashkan, Spratt, James C, Christiansen, Evald H, and Burzotta, Francesco (ORCID:0000-0002-6569-9401)
- Abstract
BackgroundImaging-guided percutaneous coronary intervention (PCI) is associated with better clinical outcomes than angiography-guided PCI. Whether routine optical coherence tomography (OCT) guidance in PCI of lesions involving coronary-artery branch points (bifurcations) improves clinical outcomes as compared with angiographic guidance is uncertain.MethodsWe conducted a multicenter, randomized, open-label trial at 38 centers in Europe. Patients with a clinical indication for PCI and a complex bifurcation lesion identified by means of coronary angiography were randomly assigned in a 1:1 ratio to OCT-guided PCI or angiography-guided PCI. The primary end point was a composite of major adverse cardiac events (MACE), defined as death from a cardiac cause, target-lesion myocardial infarction, or ischemia-driven target-lesion revascularization at a median follow-up of 2 years.ResultsWe assigned 1201 patients to OCT-guided PCI (600 patients) or angiography-guided PCI (601 patients). A total of 111 patients (18.5%) in the OCT-guided PCI group and 116 (19.3%) in the angiography-guided PCI group had a bifurcation lesion involving the left main coronary artery. At 2 years, a primary end-point event had occurred in 59 patients (10.1%) in the OCT-guided PCI group and in 83 patients (14.1%) in the angiography-guided PCI group (hazard ratio, 0.70; 95% confidence interval, 0.50 to 0.98; P=0.035). Procedure-related complications occurred in 41 patients (6.8%) in the OCT-guided PCI group and 34 patients (5.7%) in the angiography-guided PCI group.ConclusionsAmong patients with complex coronary-artery bifurcation lesions, OCT-guided PCI was associated with a lower incidence of MACE at 2 years than angiography-guided PCI. (Funded by Abbott Vascular and others; OCTOBER ClinicalTrials.gov number, NCT03171311.)In patients with coronary bifurcation lesions, optical coherence tomography-guided PCI was associated with a lower incidence of major adverse cardiac events at a median 2 years of fol
- Published
- 2023
9. Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
- Author
-
Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, Olivecrona, Goran K., Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, and Olivecrona, Goran K.
- Abstract
Background The use of percutaneous coronary intervention (PCI) to treat unprotected left main coronary artery disease has expanded rapidly in the past decade. We aimed to describe nationwide trends in clinical practice and outcomes after PCI for left main coronary artery disease. Methods and Results Patients (n=4085) enrolled in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) as undergoing PCI for left main coronary artery disease from 2005 to 2017 were included. A count regression model was used to analyze time-related differences in procedural characteristics. The 3-year major adverse cardiovascular and cerebrovascular event rate defined as death, myocardial infarction, stroke, and repeat revascularization was calculated with the Kaplan-Meier estimator and Cox proportional hazard model. The number of annual PCI procedures grew from 121 in 2005 to 589 in 2017 (389%). The increase was greater for men (479%) and individuals with diabetes (500%). Periprocedural complications occurred in 7.9%, decreasing from 10% to 6% during the study period. A major adverse cardiovascular and cerebrovascular event occurred in 35.7% of patients, falling from 45.6% to 23.9% (hazard ratio, 0.56; 95% CI, 0.41-0.78; P=0.001). Radial artery access rose from 21.5% to 74.2% and intracoronary diagnostic procedures from 14.0% to 53.3%. Use of bare-metal stents and first-generation drug-eluting stents fell from 19.0% and 71.9%, respectively, to 0, with use of new-generation drug-eluting stents increasing to 95.2%. Conclusions Recent changes in clinical practice relating to PCI for left main coronary artery disease are characterized by a 4-fold rise in procedures conducted, increased use of evidence-based adjunctive treatment strategies, intracoronary diagnostics, newer stents, and more favorable outcomes.
- Published
- 2022
- Full Text
- View/download PDF
10. Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
- Author
-
Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, Olivecrona, Goran K., Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, and Olivecrona, Goran K.
- Abstract
Background The use of percutaneous coronary intervention (PCI) to treat unprotected left main coronary artery disease has expanded rapidly in the past decade. We aimed to describe nationwide trends in clinical practice and outcomes after PCI for left main coronary artery disease. Methods and Results Patients (n=4085) enrolled in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) as undergoing PCI for left main coronary artery disease from 2005 to 2017 were included. A count regression model was used to analyze time-related differences in procedural characteristics. The 3-year major adverse cardiovascular and cerebrovascular event rate defined as death, myocardial infarction, stroke, and repeat revascularization was calculated with the Kaplan-Meier estimator and Cox proportional hazard model. The number of annual PCI procedures grew from 121 in 2005 to 589 in 2017 (389%). The increase was greater for men (479%) and individuals with diabetes (500%). Periprocedural complications occurred in 7.9%, decreasing from 10% to 6% during the study period. A major adverse cardiovascular and cerebrovascular event occurred in 35.7% of patients, falling from 45.6% to 23.9% (hazard ratio, 0.56; 95% CI, 0.41-0.78; P=0.001). Radial artery access rose from 21.5% to 74.2% and intracoronary diagnostic procedures from 14.0% to 53.3%. Use of bare-metal stents and first-generation drug-eluting stents fell from 19.0% and 71.9%, respectively, to 0, with use of new-generation drug-eluting stents increasing to 95.2%. Conclusions Recent changes in clinical practice relating to PCI for left main coronary artery disease are characterized by a 4-fold rise in procedures conducted, increased use of evidence-based adjunctive treatment strategies, intracoronary diagnostics, newer stents, and more favorable outcomes.
- Published
- 2022
- Full Text
- View/download PDF
11. Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
- Author
-
Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, Olivecrona, Goran K., Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, and Olivecrona, Goran K.
- Abstract
Background The use of percutaneous coronary intervention (PCI) to treat unprotected left main coronary artery disease has expanded rapidly in the past decade. We aimed to describe nationwide trends in clinical practice and outcomes after PCI for left main coronary artery disease. Methods and Results Patients (n=4085) enrolled in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) as undergoing PCI for left main coronary artery disease from 2005 to 2017 were included. A count regression model was used to analyze time-related differences in procedural characteristics. The 3-year major adverse cardiovascular and cerebrovascular event rate defined as death, myocardial infarction, stroke, and repeat revascularization was calculated with the Kaplan-Meier estimator and Cox proportional hazard model. The number of annual PCI procedures grew from 121 in 2005 to 589 in 2017 (389%). The increase was greater for men (479%) and individuals with diabetes (500%). Periprocedural complications occurred in 7.9%, decreasing from 10% to 6% during the study period. A major adverse cardiovascular and cerebrovascular event occurred in 35.7% of patients, falling from 45.6% to 23.9% (hazard ratio, 0.56; 95% CI, 0.41-0.78; P=0.001). Radial artery access rose from 21.5% to 74.2% and intracoronary diagnostic procedures from 14.0% to 53.3%. Use of bare-metal stents and first-generation drug-eluting stents fell from 19.0% and 71.9%, respectively, to 0, with use of new-generation drug-eluting stents increasing to 95.2%. Conclusions Recent changes in clinical practice relating to PCI for left main coronary artery disease are characterized by a 4-fold rise in procedures conducted, increased use of evidence-based adjunctive treatment strategies, intracoronary diagnostics, newer stents, and more favorable outcomes.
- Published
- 2022
- Full Text
- View/download PDF
12. Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
- Author
-
Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, Olivecrona, Goran K., Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, and Olivecrona, Goran K.
- Abstract
Background The use of percutaneous coronary intervention (PCI) to treat unprotected left main coronary artery disease has expanded rapidly in the past decade. We aimed to describe nationwide trends in clinical practice and outcomes after PCI for left main coronary artery disease. Methods and Results Patients (n=4085) enrolled in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) as undergoing PCI for left main coronary artery disease from 2005 to 2017 were included. A count regression model was used to analyze time-related differences in procedural characteristics. The 3-year major adverse cardiovascular and cerebrovascular event rate defined as death, myocardial infarction, stroke, and repeat revascularization was calculated with the Kaplan-Meier estimator and Cox proportional hazard model. The number of annual PCI procedures grew from 121 in 2005 to 589 in 2017 (389%). The increase was greater for men (479%) and individuals with diabetes (500%). Periprocedural complications occurred in 7.9%, decreasing from 10% to 6% during the study period. A major adverse cardiovascular and cerebrovascular event occurred in 35.7% of patients, falling from 45.6% to 23.9% (hazard ratio, 0.56; 95% CI, 0.41-0.78; P=0.001). Radial artery access rose from 21.5% to 74.2% and intracoronary diagnostic procedures from 14.0% to 53.3%. Use of bare-metal stents and first-generation drug-eluting stents fell from 19.0% and 71.9%, respectively, to 0, with use of new-generation drug-eluting stents increasing to 95.2%. Conclusions Recent changes in clinical practice relating to PCI for left main coronary artery disease are characterized by a 4-fold rise in procedures conducted, increased use of evidence-based adjunctive treatment strategies, intracoronary diagnostics, newer stents, and more favorable outcomes.
- Published
- 2022
- Full Text
- View/download PDF
13. Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
- Author
-
Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, Olivecrona, Goran K., Mohammad, Moman A., Persson, Jonas, Buccheri, Sergio, Odenstedt, Jacob, Sarno, Giovanna, Angeras, Oskar, Volz, Sebastian, Todt, Tim, Gotberg, Matthias, Isma, Nazim, Yndigegn, Troels, Tyden, Patrik, Venetsanos, Dimitrios, Birgander, Mats, and Olivecrona, Goran K.
- Abstract
Background The use of percutaneous coronary intervention (PCI) to treat unprotected left main coronary artery disease has expanded rapidly in the past decade. We aimed to describe nationwide trends in clinical practice and outcomes after PCI for left main coronary artery disease. Methods and Results Patients (n=4085) enrolled in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) as undergoing PCI for left main coronary artery disease from 2005 to 2017 were included. A count regression model was used to analyze time-related differences in procedural characteristics. The 3-year major adverse cardiovascular and cerebrovascular event rate defined as death, myocardial infarction, stroke, and repeat revascularization was calculated with the Kaplan-Meier estimator and Cox proportional hazard model. The number of annual PCI procedures grew from 121 in 2005 to 589 in 2017 (389%). The increase was greater for men (479%) and individuals with diabetes (500%). Periprocedural complications occurred in 7.9%, decreasing from 10% to 6% during the study period. A major adverse cardiovascular and cerebrovascular event occurred in 35.7% of patients, falling from 45.6% to 23.9% (hazard ratio, 0.56; 95% CI, 0.41-0.78; P=0.001). Radial artery access rose from 21.5% to 74.2% and intracoronary diagnostic procedures from 14.0% to 53.3%. Use of bare-metal stents and first-generation drug-eluting stents fell from 19.0% and 71.9%, respectively, to 0, with use of new-generation drug-eluting stents increasing to 95.2%. Conclusions Recent changes in clinical practice relating to PCI for left main coronary artery disease are characterized by a 4-fold rise in procedures conducted, increased use of evidence-based adjunctive treatment strategies, intracoronary diagnostics, newer stents, and more favorable outcomes.
- Published
- 2022
- Full Text
- View/download PDF
14. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention : insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Völz, Sebastian, Redfors, Björn, Angerås, Oskar, Ioanes, Dan, Odenstedt, Jacob, Koul, Sasha, Valeljung, Inger, Dworeck, Christian, Hofmann, Robin, Hansson, Emma, Venetsanos, Dimitrios, Ulvenstam, Anders, Jernberg, Tomas, Råmunddal, Truls, Pétursson, Pétur, Fröbert, Ole, Erlinge, David, Jeppsson, Anders, Omerovic, Elmir, Völz, Sebastian, Redfors, Björn, Angerås, Oskar, Ioanes, Dan, Odenstedt, Jacob, Koul, Sasha, Valeljung, Inger, Dworeck, Christian, Hofmann, Robin, Hansson, Emma, Venetsanos, Dimitrios, Ulvenstam, Anders, Jernberg, Tomas, Råmunddal, Truls, Pétursson, Pétur, Fröbert, Ole, Erlinge, David, Jeppsson, Anders, and Omerovic, Elmir
- Abstract
AIMS: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease. METHODS AND RESULTS: We analysed all-cause mortality following CABG or PCI in patients with heart failure with reduced ejection fraction and multivessel disease (coronary artery stenosis >50% in ≥2 vessels or left main) who underwent coronary angiography between 2000 and 2018 in Sweden. We used a propensity score-adjusted logistic and Cox proportional-hazards regressions and instrumental variable model to adjust for known and unknown confounders. Multilevel modelling was used to adjust for the clustering of observations in a hierarchical database. In total, 2509 patients (82.9% men) were included; 35.8% had diabetes and 34.7% had a previous myocardial infarction. The mean age was 68.1 ± 9.4 years (47.8% were >70 years old), and 64.9% had three-vessel or left main disease. Primary designated therapy was PCI in 56.2% and CABG in 43.8%. Median follow-up time was 3.9 years (range 1 day to 10 years). There were 1010 deaths. Risk of death was lower after CABG than after PCI [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.41-0.96; P = 0.031]. The risk of death increased linearly with quintiles of hospitals in which PCI was the preferred method for revascularization (OR 1.27, 95% CI 1.17-1.38, Ptrend < 0.001). CONCLUSION: In patients with ischaemic heart failure, long-term survival was greater after CABG than after PCI.
- Published
- 2021
- Full Text
- View/download PDF
15. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention : insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Völz, Sebastian, Redfors, Björn, Angerås, Oskar, Ioanes, Dan, Odenstedt, Jacob, Koul, Sasha, Valeljung, Inger, Dworeck, Christian, Hofmann, Robin, Hansson, Emma, Venetsanos, Dimitrios, Ulvenstam, Anders, Jernberg, Tomas, Råmunddal, Truls, Pétursson, Pétur, Fröbert, Ole, Erlinge, David, Jeppsson, Anders, Omerovic, Elmir, Völz, Sebastian, Redfors, Björn, Angerås, Oskar, Ioanes, Dan, Odenstedt, Jacob, Koul, Sasha, Valeljung, Inger, Dworeck, Christian, Hofmann, Robin, Hansson, Emma, Venetsanos, Dimitrios, Ulvenstam, Anders, Jernberg, Tomas, Råmunddal, Truls, Pétursson, Pétur, Fröbert, Ole, Erlinge, David, Jeppsson, Anders, and Omerovic, Elmir
- Abstract
AIMS: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease. METHODS AND RESULTS: We analysed all-cause mortality following CABG or PCI in patients with heart failure with reduced ejection fraction and multivessel disease (coronary artery stenosis >50% in ≥2 vessels or left main) who underwent coronary angiography between 2000 and 2018 in Sweden. We used a propensity score-adjusted logistic and Cox proportional-hazards regressions and instrumental variable model to adjust for known and unknown confounders. Multilevel modelling was used to adjust for the clustering of observations in a hierarchical database. In total, 2509 patients (82.9% men) were included; 35.8% had diabetes and 34.7% had a previous myocardial infarction. The mean age was 68.1 ± 9.4 years (47.8% were >70 years old), and 64.9% had three-vessel or left main disease. Primary designated therapy was PCI in 56.2% and CABG in 43.8%. Median follow-up time was 3.9 years (range 1 day to 10 years). There were 1010 deaths. Risk of death was lower after CABG than after PCI [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.41-0.96; P = 0.031]. The risk of death increased linearly with quintiles of hospitals in which PCI was the preferred method for revascularization (OR 1.27, 95% CI 1.17-1.38, Ptrend < 0.001). CONCLUSION: In patients with ischaemic heart failure, long-term survival was greater after CABG than after PCI.
- Published
- 2021
- Full Text
- View/download PDF
16. Radial artery access is associated with lower mortality in patients undergoing primary PCI : a report from the SWEDEHEART registry
- Author
-
Dworeck, Christian, Redfors, Björn, Völz, Sebastian, Haraldsson, Inger, Angerås, Oskar, Råmunddal, Truls, Ioanes, Dan, Myredal, Anna, Odenstedt, Jacob, Hirlekar, Geir, Koul, Sasha, Fröbert, Ole, Linder, Rickard, Venetsanos, Dimitrios, Hofmann, Robin, Ulvenstam, Anders, Petursson, Petur, Sarno, Giovanna, James, Stefan, Erlinge, David, Omerovic, Elmir, Dworeck, Christian, Redfors, Björn, Völz, Sebastian, Haraldsson, Inger, Angerås, Oskar, Råmunddal, Truls, Ioanes, Dan, Myredal, Anna, Odenstedt, Jacob, Hirlekar, Geir, Koul, Sasha, Fröbert, Ole, Linder, Rickard, Venetsanos, Dimitrios, Hofmann, Robin, Ulvenstam, Anders, Petursson, Petur, Sarno, Giovanna, James, Stefan, Erlinge, David, and Omerovic, Elmir
- Abstract
Objectives The purpose of this observational study was to evaluate the effects of radial artery access versus femoral artery access on the risk of 30-day mortality, inhospital bleeding and cardiogenic shock in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods We used data from the SWEDEHEART registry and included all patients who were treated with primary percutaneous coronary intervention in Sweden between 2005 and 2016. We compared patients who had percutaneous coronary intervention by radial access versus femoral access with regard to the primary endpoint of all-cause death within 30 days, using a multilevel propensity score adjusted logistic regression which included hospital as a random effect. Results During the study period, 44,804 patients underwent primary percutaneous coronary intervention of whom 24,299 (54.2%) had radial access and 20,505 (45.8%) femoral access. There were 2487 (5.5%) deaths within 30 days, of which 920 (3.8%) occurred in the radial access and 1567 (7.6%) in the femoral access group. After propensity score adjustment, radial access was associated with a lower risk of death (adjusted odds ratio (OR) 0.70, 95% confidence interval (CI) 0.55–0.88, P = 0.025). We found no interaction between access site and age, gender and cardiogenic shock regarding 30-day mortality. Radial access was also associated with a lower adjusted risk of bleeding (adjusted OR 0.45, 95% CI 0.25–0.79, P = 0.006) and cardiogenic shock (adjusted OR 0.41, 95% CI 0.24–0.73, P = 0.002). Conclusions In patients with ST-elevation myocardial infarction, primary percutaneous coronary intervention by radial access rather than femoral access was associated with an adjusted lower risk of death, bleeding and cardiogenic shock. Our findings are consistent with, and add external validity to, recent randomised trials.
- Published
- 2020
- Full Text
- View/download PDF
17. Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Garot, Philippe, Iriart, Xavier, Aminian, Adel, Kefer, Joëlle, Freixa, Xavier, Cruz-Gonzalez, Ignacio, Berti, Sergio, Rosseel, Liesbeth, Ibrahim, Reda, Korsholm, Kasper, Odenstedt, Jacob, Nielsen-Kudsk, Jens-Erik, Saw, Jaqueline, Sondergaard, Lars, De Backer, Ole, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Garot, Philippe, Iriart, Xavier, Aminian, Adel, Kefer, Joëlle, Freixa, Xavier, Cruz-Gonzalez, Ignacio, Berti, Sergio, Rosseel, Liesbeth, Ibrahim, Reda, Korsholm, Kasper, Odenstedt, Jacob, Nielsen-Kudsk, Jens-Erik, Saw, Jaqueline, Sondergaard, Lars, and De Backer, Ole
- Abstract
BACKGROUND: Optimal preprocedural planning is essential to ensure successful device closure of the left atrial appendage (LAA). DESIGN: The PREDICT-LAA study is a prospective, international, multicentre, randomised controlled trial (ClinicalTrials.gov NCT04180605). Two hundred patients eligible for LAA closure with an Amplatzer Amulet device (Abbott, USA) will be enrolled in the study. Patients will be allocated to a computational simulation arm (experimental) or standard treatment arm (control) using a 1:1 randomisation. For patients randomised to the computational simulation arm, preprocedural planning will be based on the analysis of cardiac computed tomography (CCT)-based patient-specific computational simulations (FEops HEARTguide, Ghent, Belgium) in order to predict optimal device size and position. For patients in the control arm, preprocedural planning will be based on local practice including CCT analysis. The LAA closure procedure and postprocedural antithrombotic therapy will follow local practice in both arms. The primary endpoint of the study is incomplete LAA closure and device-related thrombus as assessed at 3 months postprocedural CCT. Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months. CONCLUSION: The objective of the PREDICT-LAA study is to test the hypothesis that a preprocedural planning for LAA closure with the Amplatzer Amulet device based on patient-specific computational simulations can result in a more efficient procedure, optimised procedural outcomes and better clinical outcomes as compared with a standard preprocedural planning. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04180605).
- Published
- 2020
18. Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device:rationale and design of the PREDICT-LAA study
- Author
-
Garot, Philippe, Iriart, Xavier, Aminian, Adel, Kefer, Joelle, Freixa, Xavier, Cruz-Gonzalez, Ignacio, Berti, Sergio, Rosseel, Liesbeth, Ibrahim, Reda, Korsholm, Kasper, Odenstedt, Jacob, Nielsen-Kudsk, Jens-Erik, Saw, Jaqueline, Sondergaard, Lars, De Backer, Ole, Garot, Philippe, Iriart, Xavier, Aminian, Adel, Kefer, Joelle, Freixa, Xavier, Cruz-Gonzalez, Ignacio, Berti, Sergio, Rosseel, Liesbeth, Ibrahim, Reda, Korsholm, Kasper, Odenstedt, Jacob, Nielsen-Kudsk, Jens-Erik, Saw, Jaqueline, Sondergaard, Lars, and De Backer, Ole
- Abstract
BACKGROUND: Optimal preprocedural planning is essential to ensure successful device closure of the left atrial appendage (LAA).DESIGN: The PREDICT-LAA study is a prospective, international, multicentre, randomised controlled trial (ClinicalTrials.gov NCT04180605). Two hundred patients eligible for LAA closure with an Amplatzer Amulet device (Abbott, USA) will be enrolled in the study. Patients will be allocated to a computational simulation arm (experimental) or standard treatment arm (control) using a 1:1 randomisation. For patients randomised to the computational simulation arm, preprocedural planning will be based on the analysis of cardiac computed tomography (CCT)-based patient-specific computational simulations (FEops HEARTguide, Ghent, Belgium) in order to predict optimal device size and position. For patients in the control arm, preprocedural planning will be based on local practice including CCT analysis. The LAA closure procedure and postprocedural antithrombotic therapy will follow local practice in both arms. The primary endpoint of the study is incomplete LAA closure and device-related thrombus as assessed at 3 months postprocedural CCT. Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months.CONCLUSION: The objective of the PREDICT-LAA study is to test the hypothesis that a preprocedural planning for LAA closure with the Amplatzer Amulet device based on patient-specific computational simulations can result in a more efficient procedure, optimised procedural outcomes and better clinical outcomes as compared with a standard preprocedural planning.TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04180605).
- Published
- 2020
19. Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device:rationale and design of the PREDICT-LAA study
- Author
-
Garot, Philippe, Iriart, Xavier, Aminian, Adel, Kefer, Joelle, Freixa, Xavier, Cruz-Gonzalez, Ignacio, Berti, Sergio, Rosseel, Liesbeth, Ibrahim, Reda, Korsholm, Kasper, Odenstedt, Jacob, Nielsen-Kudsk, Jens-Erik, Saw, Jaqueline, Sondergaard, Lars, De Backer, Ole, Garot, Philippe, Iriart, Xavier, Aminian, Adel, Kefer, Joelle, Freixa, Xavier, Cruz-Gonzalez, Ignacio, Berti, Sergio, Rosseel, Liesbeth, Ibrahim, Reda, Korsholm, Kasper, Odenstedt, Jacob, Nielsen-Kudsk, Jens-Erik, Saw, Jaqueline, Sondergaard, Lars, and De Backer, Ole
- Abstract
BACKGROUND: Optimal preprocedural planning is essential to ensure successful device closure of the left atrial appendage (LAA).DESIGN: The PREDICT-LAA study is a prospective, international, multicentre, randomised controlled trial (ClinicalTrials.gov NCT04180605). Two hundred patients eligible for LAA closure with an Amplatzer Amulet device (Abbott, USA) will be enrolled in the study. Patients will be allocated to a computational simulation arm (experimental) or standard treatment arm (control) using a 1:1 randomisation. For patients randomised to the computational simulation arm, preprocedural planning will be based on the analysis of cardiac computed tomography (CCT)-based patient-specific computational simulations (FEops HEARTguide, Ghent, Belgium) in order to predict optimal device size and position. For patients in the control arm, preprocedural planning will be based on local practice including CCT analysis. The LAA closure procedure and postprocedural antithrombotic therapy will follow local practice in both arms. The primary endpoint of the study is incomplete LAA closure and device-related thrombus as assessed at 3 months postprocedural CCT. Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months.CONCLUSION: The objective of the PREDICT-LAA study is to test the hypothesis that a preprocedural planning for LAA closure with the Amplatzer Amulet device based on patient-specific computational simulations can result in a more efficient procedure, optimised procedural outcomes and better clinical outcomes as compared with a standard preprocedural planning.TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04180605).
- Published
- 2020
20. Radial artery access is associated with lower mortality in patients undergoing primary PCI : a report from the SWEDEHEART registry
- Author
-
Dworeck, Christian, Redfors, Björn, Völz, Sebastian, Haraldsson, Inger, Angerås, Oskar, Råmunddal, Truls, Ioanes, Dan, Myredal, Anna, Odenstedt, Jacob, Hirlekar, Geir, Koul, Sasha, Fröbert, Ole, Linder, Rickard, Venetsanos, Dimitrios, Hofmann, Robin, Ulvenstam, Anders, Petursson, Petur, Sarno, Giovanna, James, Stefan, Erlinge, David, Omerovic, Elmir, Dworeck, Christian, Redfors, Björn, Völz, Sebastian, Haraldsson, Inger, Angerås, Oskar, Råmunddal, Truls, Ioanes, Dan, Myredal, Anna, Odenstedt, Jacob, Hirlekar, Geir, Koul, Sasha, Fröbert, Ole, Linder, Rickard, Venetsanos, Dimitrios, Hofmann, Robin, Ulvenstam, Anders, Petursson, Petur, Sarno, Giovanna, James, Stefan, Erlinge, David, and Omerovic, Elmir
- Abstract
Objectives: The purpose of this observational study was to evaluate the effects of radial artery access versus femoral artery access on the risk of 30-day mortality, inhospital bleeding and cardiogenic shock in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods: We used data from the SWEDEHEART registry and included all patients who were treated with primary percutaneous coronary intervention in Sweden between 2005 and 2016. We compared patients who had percutaneous coronary intervention by radial access versus femoral access with regard to the primary endpoint of all-cause death within 30 days, using a multilevel propensity score adjusted logistic regression which included hospital as a random effect. Results: During the study period, 44,804 patients underwent primary percutaneous coronary intervention of whom 24,299 (54.2%) had radial access and 20,505 (45.8%) femoral access. There were 2487 (5.5%) deaths within 30 days, of which 920 (3.8%) occurred in the radial access and 1567 (7.6%) in the femoral access group. After propensity score adjustment, radial access was associated with a lower risk of death (adjusted odds ratio (OR) 0.70, 95% confidence interval (CI) 0.55-0.88,P = 0.025). We found no interaction between access site and age, gender and cardiogenic shock regarding 30-day mortality. Radial access was also associated with a lower adjusted risk of bleeding (adjusted OR 0.45, 95% CI 0.25-0.79,P = 0.006) and cardiogenic shock (adjusted OR 0.41, 95% CI 0.24-0.73,P = 0.002). Conclusions: In patients with ST-elevation myocardial infarction, primary percutaneous coronary intervention by radial access rather than femoral access was associated with an adjusted lower risk of death, bleeding and cardiogenic shock. Our findings are consistent with, and add external validity to, recent randomised trials., Funding Agency:ALF Göteborg
- Published
- 2020
- Full Text
- View/download PDF
21. PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
- Author
-
Haraldsson,Inger, Gan,Li-Ming, Svedlund,Sara, Torngren,Kristina, Westergren,Helena U., Redfors,Björn, Lagerström-Fermer,Maria, Angerås,Oskar, Råmunddal,Truls, Petursson,Petur, Odenstedt,Jacob, Albertsson,Per, Erlinge,David, Omerovic,Elmir, Haraldsson,Inger, Gan,Li-Ming, Svedlund,Sara, Torngren,Kristina, Westergren,Helena U., Redfors,Björn, Lagerström-Fermer,Maria, Angerås,Oskar, Råmunddal,Truls, Petursson,Petur, Odenstedt,Jacob, Albertsson,Per, Erlinge,David, and Omerovic,Elmir
- Abstract
Inger Haraldsson,1,2 Li-Ming Gan,1–3 Sara Svedlund,1,4 Kristina Torngren,5 Helena U Westergren,6 Björn Redfors,1,2 Maria Lagerström-Fermér,3 Oskar Angerås,1,2 Truls Råmunddal,1,2 Petur Petursson,1,2 Jacob Odenstedt,1,2 Per Albertsson,1,2 David Erlinge,5 Elmir Omerovic1,21Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; 3Early Clinical Development, IMED Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden; 4Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden; 5Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden; 6Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca R&D, Gothenburg, SwedenCorrespondence: Elmir OmerovicDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Bruna stråket 16, 41345 Gothenburg, SwedenTel +46 31 342 2950Fax +46 3 182 3762Email elmir@wlab.gu.seBackground: Survivors of myocardial infarction (MI) are at high risk of new major adverse cardiovascular events (MACE). Coronary flow reserve (CFR) is a strong and independent predictor of MACE. Understanding the prevalence of impaired CFR in this patient group and identifying risk markers for impaired CFR are important steps in the development of personalized and targeted treatment for high-risk individuals with prior MI.Methods: PROFLOW is a prospective, exploratory, cross-sectional open study. We used information from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) to identify high-risk patients with a history of type-1 MI. We measured CFR non-invasively in a left anterior descending artery (LAD) using transthoracic Doppler echocardiography. Coronary flow velocity was measured at rest and at maximal flow af
- Published
- 2019
22. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry
- Author
-
Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, Omerovic, Elmir, Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir
- Abstract
Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results-We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P<0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P<0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions-Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
- Published
- 2018
- Full Text
- View/download PDF
23. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry
- Author
-
Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, Omerovic, Elmir, Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir
- Abstract
Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results-We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P<0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P<0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions-Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
- Published
- 2018
- Full Text
- View/download PDF
24. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry
- Author
-
Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, Omerovic, Elmir, Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir
- Abstract
Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results-We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P<0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P<0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions-Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
- Published
- 2018
- Full Text
- View/download PDF
25. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry
- Author
-
Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, Omerovic, Elmir, Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir
- Abstract
Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results-We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P<0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P<0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions-Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
- Published
- 2018
- Full Text
- View/download PDF
26. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry
- Author
-
Angerås, Oskar, Haraldsson, Inger, Redfors, Björn, Fröbert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Rück, Andreas, Millgård, Jonas, Nilsson, Johan, Persson, Jonas, Söderbom, Måns, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, Omerovic, Elmir, Angerås, Oskar, Haraldsson, Inger, Redfors, Björn, Fröbert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Rück, Andreas, Millgård, Jonas, Nilsson, Johan, Persson, Jonas, Söderbom, Måns, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir
- Abstract
Background: Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results: We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P<0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P<0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions: Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality., Funding Agencies:ALF Västra Götaland University of Gothenburg, Sweden ALFGBG 141131
- Published
- 2018
- Full Text
- View/download PDF
27. Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction : A Report From the Swedish Coronary Angiography and Angioplasty Registry
- Author
-
Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, Omerovic, Elmir, Angeras, Oskar, Haraldsson, Inger, Redfors, Bjorn, Frobert, Ole, Petursson, Petur, Albertsson, Per, Ioanes, Dan, Odenstedt, Jacob, Olsson, Hans, Witt, Nils, Ruck, Andreas, Millgard, Jonas, Nilsson, Johan, Persson, Jonas, Soderbom, Mans, Wedel, Hans, Erlinge, David, James, Stefan, Ramunddal, Truls, and Omerovic, Elmir
- Abstract
Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results-We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P<0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P<0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions-Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
- Published
- 2018
- Full Text
- View/download PDF
28. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage : a propensity score-matched follow-up study
- Author
-
Nielsen-Kudsk, Jens Erik, Johnsen, Soren Paaske, Wester, Per, Damgaard, Dorte, Airaksinen, Juhani, Lund, Juha, De Backer, Ole, Pakarinen, Sami, Odenstedt, Jacob, Vikman, Saila, Settergren, Magnus, Kongstad, Ole, Rosenqvist, Marten, Krieger, Derk W., Nielsen-Kudsk, Jens Erik, Johnsen, Soren Paaske, Wester, Per, Damgaard, Dorte, Airaksinen, Juhani, Lund, Juha, De Backer, Ole, Pakarinen, Sami, Odenstedt, Jacob, Vikman, Saila, Settergren, Magnus, Kongstad, Ole, Rosenqvist, Marten, and Krieger, Derk W.
- Abstract
Aims: The aim of this study was to investigate the prognosis in patients with atrial fibrillation (AF) and intracerebral haemorrhage (ICH) having a left atrial appendage occlusion (LAAO) versus patients receiving standard medical therapy. Methods and results: A total of 151 patients from the Nordic countries with AF and previous ICH who underwent LAAO using the AMPLATZER Cardiac Plug or the AMPLATZER AMULET were compared to a propensity score-matched group of 151 patients receiving standard medical therapy. The two groups were matched so that their risks for stroke and bleeding were similar (CHA2DS2-VASc and HAS-BLED scores). The standard care patients were identified from the Danish Stroke Registry among 787 patients with AF and ICH. The primary endpoint was a composite of all-cause mortality, ischaemic stroke and major bleeding. Patients with AF and a prior ICH treated with LAAO had a lower risk of the composite outcome as compared to patients treated with standard medical care (events/1,000 years [95% confidence interval]: 53.3 [44.3-64.1] vs. 366.7 [298.2-450.9]; hazard ratio 0.16 [0.07-0.37]). Conclusions: LAAO is suggested to be of major clinical benefit in AF patients having sustained an ICH. These results have to be confirmed in a randomised clinical trial.
- Published
- 2017
- Full Text
- View/download PDF
29. Different Risk Factor Profile In Young Versus Older Patients With Acute Coronary Syndrome : A Swedish Coronary Angiography And Angioplasty Registry Study
- Author
-
Lindholm, Daniel, James, Stefan, Odenstedt, Jacob, Johnston, Nina, Persson, Jonas, Venetsanos, Dimitrios, Lagerqvist, Bo, Varenhorst, Christoph, Lindholm, Daniel, James, Stefan, Odenstedt, Jacob, Johnston, Nina, Persson, Jonas, Venetsanos, Dimitrios, Lagerqvist, Bo, and Varenhorst, Christoph
- Abstract
Det finns två Jonas Persson på universitetet
- Published
- 2015
- Full Text
- View/download PDF
30. Chronic Total Occlusions in Sweden - A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, and Omerovic, Elmir
- Abstract
Introduction: Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden. Methods and Results: Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be >= 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG. Conclusion: CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients.
- Published
- 2014
- Full Text
- View/download PDF
31. Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
- Author
-
Lagerqvist, Bo, Frobert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Todt, Tim, Zelleroth, Eva, Östlund, Ollie, James, Stefan K., Lagerqvist, Bo, Frobert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Todt, Tim, Zelleroth, Eva, Östlund, Ollie, and James, Stefan K.
- Abstract
BACKGROUND Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year.
- Published
- 2014
- Full Text
- View/download PDF
32. Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
- Author
-
Lagerqvist, Bo, Fröbert, Ole, Olivecrona, Göran K., Gudnason, Thórarinn, Maeng, Michael, Alström, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jörg, Collste, Olov, Götberg, Matthias, Hårdhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Östlund, Ollie, James, Stefan K., Lagerqvist, Bo, Fröbert, Ole, Olivecrona, Göran K., Gudnason, Thórarinn, Maeng, Michael, Alström, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jörg, Collste, Olov, Götberg, Matthias, Hårdhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Östlund, Ollie, and James, Stefan K.
- Abstract
BACKGROUND Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year.
- Published
- 2014
- Full Text
- View/download PDF
33. Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
- Author
-
Lagerqvist, Bo, Frobert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Ostlund, Ollie, James, Stefan K., Lagerqvist, Bo, Frobert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Ostlund, Ollie, and James, Stefan K.
- Abstract
BACKGROUND Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year., Funding Agencies|Swedish Research Council; Swedish Association of Local Authorities and Regions; Terumo Medical; Medtronic; Vascular Solutions; Swedish Heart-Lung Foundation [20100178, B0010401]; Landspitali University Hospital
- Published
- 2014
- Full Text
- View/download PDF
34. Chronic Total Occlusions in Sweden - A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, and Omerovic, Elmir
- Abstract
Introduction: Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden. Methods and Results: Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be >= 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG. Conclusion: CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients.
- Published
- 2014
- Full Text
- View/download PDF
35. Chronic Total Occlusions in Sweden - A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, and Omerovic, Elmir
- Abstract
Introduction: Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden. Methods and Results: Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be >= 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG. Conclusion: CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients.
- Published
- 2014
- Full Text
- View/download PDF
36. Chronic Total Occlusions in Sweden - A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, and Omerovic, Elmir
- Abstract
Introduction: Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden. Methods and Results: Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be >= 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG. Conclusion: CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients.
- Published
- 2014
- Full Text
- View/download PDF
37. Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
- Author
-
Lagerqvist, Bo, Frobert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Ostlund, Ollie, James, Stefan K., Lagerqvist, Bo, Frobert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Ostlund, Ollie, and James, Stefan K.
- Abstract
BACKGROUND Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year., Funding Agencies|Swedish Research Council; Swedish Association of Local Authorities and Regions; Terumo Medical; Medtronic; Vascular Solutions; Swedish Heart-Lung Foundation [20100178, B0010401]; Landspitali University Hospital
- Published
- 2014
- Full Text
- View/download PDF
38. Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
- Author
-
Lagerqvist, Bo, Frobert, Ole, Olivecrona, Göran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jörg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Todt, Tim, Zelleroth, Eva, Ostlund, Ollie, James, Stefan K., Lagerqvist, Bo, Frobert, Ole, Olivecrona, Göran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jörg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Todt, Tim, Zelleroth, Eva, Ostlund, Ollie, and James, Stefan K.
- Abstract
BACKGROUND Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year.
- Published
- 2014
- Full Text
- View/download PDF
39. Chronic Total Occlusions in Sweden - A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Goran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, and Omerovic, Elmir
- Abstract
Introduction: Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden. Methods and Results: Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be >= 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG. Conclusion: CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients.
- Published
- 2014
- Full Text
- View/download PDF
40. Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
- Author
-
Lagerqvist, Bo, Fröbert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Todt, Tim, Zelleroth, Eva, Ostlund, Ollie, James, Stefan K., Lagerqvist, Bo, Fröbert, Ole, Olivecrona, Goran K., Gudnason, Thorarinn, Maeng, Michael, Alstrom, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jorg, Collste, Olov, Gotberg, Matthias, Hardhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Todt, Tim, Zelleroth, Eva, Ostlund, Ollie, and James, Stefan K.
- Abstract
BACKGROUND: Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS: We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS: No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS: Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year.
- Published
- 2014
- Full Text
- View/download PDF
41. Outcomes 1 year after thrombus aspiration for myocardial infarction.
- Author
-
Lagerqvist, Bo, Fröbert, Ole, Olivecrona, Göran, Gudnason, Thórarinn, Maeng, Michael, Alström, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jörg, Collste, Olov, Götberg, Matthias, Hårdhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Östlund, Ollie, James, Stefan K, Lagerqvist, Bo, Fröbert, Ole, Olivecrona, Göran, Gudnason, Thórarinn, Maeng, Michael, Alström, Patrik, Andersson, Jonas, Calais, Fredrik, Carlsson, Jörg, Collste, Olov, Götberg, Matthias, Hårdhammar, Peter, Ioanes, Dan, Kallryd, Anders, Linder, Rickard, Lundin, Anders, Odenstedt, Jacob, Omerovic, Elmir, Puskar, Verner, Tödt, Tim, Zelleroth, Eva, Östlund, Ollie, and James, Stefan K
- Abstract
Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration.
- Published
- 2014
42. Chronic Total Occlusions in Sweden - A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Göran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Henriques, Jose P. S., Dworeck, Christian, Angeras, Oskar, Odenstedt, Jacob, Ioanes, Dan, Olivecrona, Göran, Harnek, Jan, Jensen, Ulf, Aasa, Mikael, Jussila, Risto, James, Stefan, Lagerqvist, Bo, Matejka, Goran, Albertsson, Per, and Omerovic, Elmir
- Abstract
Introduction: Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden. Methods and Results: Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be >= 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG. Conclusion: CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients.
- Published
- 2014
43. Chronic Total Occlusions in Sweden : Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Ramunddal, Truls, Hoebers, Loes, Dworeck, Christian, Angeras, Oskar, Ioanes, Dan, Odenstedt, Jacob, Jussila, Risto, Jensen, Ulf, Harnek, Jan, Olivecrona, Goran, Tijssen, Jan, Henriques, Jose, Aasa, Mkael, James, Stefan, Albertsson, Per, Omerovic, Elmir, Ramunddal, Truls, Hoebers, Loes, Dworeck, Christian, Angeras, Oskar, Ioanes, Dan, Odenstedt, Jacob, Jussila, Risto, Jensen, Ulf, Harnek, Jan, Olivecrona, Goran, Tijssen, Jan, Henriques, Jose, Aasa, Mkael, James, Stefan, Albertsson, Per, and Omerovic, Elmir
- Published
- 2012
- Full Text
- View/download PDF
44. Opioid receptor agonist Eribis peptide 94 reduces infarct size in different porcine models for myocardial ischaemia and reperfusion
- Author
-
Karlsson, Lars O., Grip, Lars, Bissessar, Erik, Bobrova, Irina, Gustafsson, Thomas, Kavianipour, Mohammad, Odenstedt, Jacob, Wikström, Gerhard, Gonon, Adrian T., Karlsson, Lars O., Grip, Lars, Bissessar, Erik, Bobrova, Irina, Gustafsson, Thomas, Kavianipour, Mohammad, Odenstedt, Jacob, Wikström, Gerhard, and Gonon, Adrian T.
- Abstract
Eribis peptide 94 (EP 94) is a novel enkephalin analog, thought to interact with the and delta-opioid receptors. The purpose of the present study was to examine the cardioprotective potential of EP 94 in two clinically relevant porcine models of myocardial ischaemia and reperfusion, and to investigate if such an effect is associated with an increased expression of endothelial nitric oxide synthase (eNOS). Forty-one anesthetized pigs underwent 40 min of coronary occlusion followed by 4 h of reperfusion. In Protocol I, balloon occlusion of the left anterior descending artery was performed with concurrent intravenous administration of (A) vehicle (n = 7), (B) EP 94 (1 ug/kg) after 5, 12, 19 and 26 min of ischaemia (n = 4) or (C) EP 94 (1 ug/kg) after 26, 33, 40 min of ischaemia (n = 6). In Protocol II, open-chest pigs were administered (D) vehicle (n = 6) or (E) 0.2 ug/kg/min of EP 94 (n = 6) through an intracoronary infusion into the jeopardized myocardium, started after 30 min of ischaemia and maintained for 15 min. The hearts were stained and the protein content of eNOS measured. EP 94 reduces infarct size when administered both early and late during ischaemia compared with vehicle (infarct size group A 61.6 +/- 2%, group B 50.2 +/- 3% and group C 49.2 +/- 2%, respectively, P < 0.05), as well as when infused intracoronary (infarct size group D 82.2 +/- 3.9% and group E 61.2 +/- 2.5% respectively, P < 0.01). Phosphorylated eNOS Ser(I177) in relation to total eNOS was significantly increased in the group administered EP 94. indicating activation of nitric oxide production.
- Published
- 2011
- Full Text
- View/download PDF
45. Opioid receptor agonist Eribis peptide 94 reduces infarct size in different porcine models for myocardial ischaemia and reperfusion
- Author
-
Karlsson, Lars O., Grip, Lars, Bissessar, Erik, Bobrova, Irina, Gustafsson, Thomas, Kavianipour, Mohammad, Odenstedt, Jacob, Wikstrom, Gerhard, Gonon, Adrian T., Karlsson, Lars O., Grip, Lars, Bissessar, Erik, Bobrova, Irina, Gustafsson, Thomas, Kavianipour, Mohammad, Odenstedt, Jacob, Wikstrom, Gerhard, and Gonon, Adrian T.
- Abstract
Eribis peptide 94 (EP 94) is a novel enkephalin analog, thought to interact with the and delta-opioid receptors. The purpose of the present study was to examine the cardioprotective potential of EP 94 in two clinically relevant porcine models of myocardial ischaemia and reperfusion, and to investigate if such an effect is associated with an increased expression of endothelial nitric oxide synthase (eNOS). Forty-one anesthetized pigs underwent 40 min of coronary occlusion followed by 4 h of reperfusion. In Protocol I, balloon occlusion of the left anterior descending artery was performed with concurrent intravenous administration of (A) vehicle (n = 7), (B) EP 94 (1 ug/kg) after 5, 12, 19 and 26 min of ischaemia (n = 4) or (C) EP 94 (1 ug/kg) after 26, 33, 40 min of ischaemia (n = 6). In Protocol II, open-chest pigs were administered (D) vehicle (n = 6) or (E) 0.2 ug/kg/min of EP 94 (n = 6) through an intracoronary infusion into the jeopardized myocardium, started after 30 min of ischaemia and maintained for 15 min. The hearts were stained and the protein content of eNOS measured. EP 94 reduces infarct size when administered both early and late during ischaemia compared with vehicle (infarct size group A 61.6 +/- 2%, group B 50.2 +/- 3% and group C 49.2 +/- 2%, respectively, P < 0.05), as well as when infused intracoronary (infarct size group D 82.2 +/- 3.9% and group E 61.2 +/- 2.5% respectively, P < 0.01). Phosphorylated eNOS Ser(I177) in relation to total eNOS was significantly increased in the group administered EP 94. indicating activation of nitric oxide production. (c) 2010 Elsevier B.V. All rights reserved., Funding Agencies|Eribis Pharma
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.